Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Net Cash Flow (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Net Cash Flow data on record, last reported at $2.9 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 797.22% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $3.8 million, up 1476.0%, while the annual FY2024 figure was -$936249.0, 59.68% up from the prior year.
  • Net Cash Flow reached $2.9 million in Q3 2025 per COEP's latest filing, up from -$2.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $5.0 million in Q3 2022 and bottomed at -$4.2 million in Q4 2021.
  • Average Net Cash Flow over 5 years is -$92658.5, with a median of -$122205.0 recorded in 2021.
  • Peak YoY movement for Net Cash Flow: surged 8442.3% in 2022, then plummeted 1149.16% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$4.2 million in 2021, then increased by 14.09% to -$3.6 million in 2022, then soared by 101.61% to $57624.0 in 2023, then tumbled by 1149.16% to -$604567.0 in 2024, then surged by 581.63% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $2.9 million in Q3 2025, -$2.3 million in Q2 2025, and $3.7 million in Q1 2025.